i2O Therapeutics focuses on developing GLP-1 combinations for obesity and cardio-renal-metabolic diseases, with a pipeline that includes long-acting GLP-1 receptor agonists and other related compounds
i2O Therapeutics focuses on developing GLP-1 combinations for obesity and cardio-renal-metabolic diseases, with a pipeline that includes long-acting GLP-1 receptor agonists and other related compounds.